新闻发布详细信息

NEW YORK, Sept. 7, 2016/PRNewswire/ -- Bruker today announced that it has signed an agreement to acquire the preclinical imaging business of Oncovision, a leading provider of innovative medical imaging devices used for the diagnosis of cancer. Financial terms of the agreement were not disclosed.

For the past five years, Brukerand Oncovision have partnered on an exclusive marketing agreement forAlbira™PET/SPECT/CT系统，并开发了下一代Albira Si具有高级硅光电塑料（SIPM）技术，可提供最高的全面视野宠物分辨率和灵敏度。OnCovision和 Brukerhave also collaborated on a high-performance preclinical 3 Tesla SiPM-PET/MRI system, and are exhibiting a new, simultaneous SiPM-PET/MR insert for high-field magnets at WMIC 2016 in 纽约this week.

Dr. Wulf I. Jung, President of 布鲁克的Preclinical Imaging Division, stated: "With this planned acquisition, Brukerexpects to strengthen its expertise and leadership in preclinical imaging. The unique, performance-leading SiPM PET technology and products developed by Oncovision in close collaboration with the molecular imaging institute I3M and the University of Valencia, offer outstanding spatial resolution across the full field of view (FOV), increasing the high-resolution FOV by an order of magnitude compared to traditional PET systems, thereby facilitating quantitative imaging investigations."

Dr. Jung continued: "This unique and proprietary PET technology is one of the most important imaging modalities for translational research imaging. Our successful collaboration with Oncovision has led to the recent introduction of the performance-leadingAlbira SiPET/SPECT/CT系统，现在还导致了第一个用于同时进行PET和MRI测量的高场MRI系统的PET插入物。”

Ignasi Vivas, CEO of Oncovision, commented: " Brukeris the undisputed leader in preclinical imaging with a unique portfolio of imaging modalities. Our preclinical team is delighted to join a company so well known for their innovation and dedication to excellence. The combined resources will accelerate the development and integration of our molecular imaging technologies, and fulfill the growing demand from translational scientists."

As part of the agreement, Oncovision will retain its clinical human imaging business, including the MAMMI PET, a breast cancer diagnostic device based on PET imaging. Closing of the acquisition is expected late in the fourth quarter of 2016, and is subject to closing conditions. A German-Spanish team of the law firm CMS acted as legal adviser to Bruker.

Abbreviations: PET = Positron Emission Tomography, SPECT = Single Photon Emission Computed Tomography, CT = (X-ray) Computed Tomography, MRI = Magnetic Resonance Imaging, WMIC = World Molecular Imaging Conference.

About Oncovision

Oncovision是外科医生，放射科医生，肿瘤学家和核医生使用的创新医学成像设备的领先提供商，用于诊断和治疗癌症。临床产品包括市场领先的Sentinella，一种独特的术中伽马摄像头和革命性的Mammi PET，这是一种乳腺癌诊断装置，能够可视化小于2mm的病变并量化肿瘤活性。Oncovision通过Wprobe，放射性手术的金标准和Albira Si PET/SPECT/CT/CT临床前成像系统完成了其投资组合。Oncovision在办公室里 马萨诸塞州波士顿(USA) and Valencia, Spainand sells its products in over 30 markets through a combination of direct sales and distributors. For more information, please visit:www.oncovision.com.

About Bruker Corporation(NASDAQ: BRKR)

For more than 50 years, Bruker使有技巧的ists to make breakthrough discoveries and develop new applications that improve the quality of human life. 布鲁克的high-performance scientific research instruments and high-value analytical solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Brukeris enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy, nano-analysis and industrial applications, as well as in cell biology, preclinical imaging, clinical research, microbiology and molecular diagnostics. For more information, please visit:www.energie2point0.com/preclinicalimaging

Photo -http://photos.prbob体育竞技风暴newswire.com/prnh/20160906/404441

Photo -http://photos.prbob体育竞技风暴newswire.com/prnh/20160906/404440

要在PR Newswire上查看原始版本，请访问：bob体育竞技风暴http://www.prnewswire.com/news-releases/bruker-signs-agreement-to-acquire-oncovisions-preclinical-pet-imaging-business-300323311.html

SOURCE Bruker Corporation